Everything in Moderation: Lessons Learned by Exploiting Moderate Replication Stress in Cancer

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Standard chemotherapy causes severe side effects due to poor selectivity.
• Cancer cells often have unique vulnerabilities, such as oncogene-induced replication stress.
• DNA Damage Response (DDR) inhibitors target these tumor-specific vulnerabilities.

Purpose of the Study:

• To review the clinical development of CHK1 inhibitors (CHK1i).
• To identify lessons learned from CHK1i trials.
• To guide future clinical trial design for DDR inhibitors targeting replication stress in cancer.

Main Methods:

• Review of clinical trial data for CHK1 inhibitors.
• Analysis of combination strategies involving CHK1i and replication stress inducers.
• Evaluation of toxicity and efficacy profiles.

Main Results:

• Single-agent CHK1i efficacy in trials was disappointing.
• Early combinations of CHK1i with chemotherapy were excessively toxic.
• Combining CHK1i with subclinical doses of replication stress inducers shows improved efficacy and tolerability.

Conclusions:

• CHK1 inhibitors show promise when combined with low-dose replication stress inducers.
• This approach is better tolerated and compatible with immunotherapy.
• Optimized clinical trial designs are crucial for DDR inhibitor development in cancer therapy.